Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients.
Aspergillosis
Efficacy
Galactomannan
Infectious complications in hematological malignancies
Invasive fungal infection
Neutropenia
Screening
Journal
Acta haematologica
ISSN: 1421-9662
Titre abrégé: Acta Haematol
Pays: Switzerland
ID NLM: 0141053
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
03
2023
accepted:
06
05
2023
medline:
5
10
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
ppublish
Résumé
Invasive aspergillosis (IA) affects mainly patients with hematological malignancies, and early diagnosis is crucial for timely treatment. Most diagnoses are based on clinical and mycological criteria, mostly galactomannan (GM) test in serum or bronchoalveolar fluid, which is performed in case of clinical suspicion or as routine screening in patients at high risk who are not receiving anti-mold prophylaxis, for early detection of IA. The aim of this study was to assess in a real-world setting the efficacy of biweekly serum GM screening for the early detection of IA. A retrospective cohort that included 80 adult patients treated at the Hematology Department, Hadassah Medical Center, 2016-2020, with a diagnosis of IA. Clinical and laboratory data were collected from patients' medical files and the rate of GM-driven, GM-associated, and non-GM-associated IA was calculated. There were 58 patients with IA. The rate of GM-driven diagnosis was 6.9%, GM-associated diagnosis was 43.1%, and non-GM-associated diagnosis was 56.9%. The GM test as a screening tool had led to IA diagnosis in only 0.2% of screened serums with a number needed to screen in order to find 1 patient with IA of 490. Clinical suspicion outweighs GM screening as a tool for early diagnosis of IA. Nevertheless, GM has an important role as a diagnostic tool for IA.
Identifiants
pubmed: 37231768
pii: 000531044
doi: 10.1159/000531044
pmc: PMC10614280
doi:
Substances chimiques
galactomannan
11078-30-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
358-365Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Eur J Cancer. 2003 Nov;39(17):2495-8
pubmed: 14602135
Mycoses. 2019 Mar;62(3):204-213
pubmed: 30387195
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Cochrane Database Syst Rev. 2008 Oct 08;(4):CD007394
pubmed: 18843747
Mycopathologia. 2007 Apr;163(4):191-202
pubmed: 17410480
J Clin Microbiol. 2007 Sep;45(9):3141-2
pubmed: 17670932
Blood. 2003 Aug 1;102(3):827-33
pubmed: 12689933
J Fungi (Basel). 2020 Nov 12;6(4):
pubmed: 33198419
Clin Infect Dis. 2005 Jun 15;40(12):1762-9
pubmed: 15909264
J Antimicrob Chemother. 2008 Feb;61(2):411-6
pubmed: 18055488
Clin Infect Dis. 2005 Nov 1;41(9):1242-50
pubmed: 16206097
J Pak Med Assoc. 2020 Mar;70(3):442-446
pubmed: 32207422
N Engl J Med. 2013 Jul 4;369(1):97-8
pubmed: 23822795
Front Med (Lausanne). 2021 Feb 15;8:631461
pubmed: 33659265
Semin Respir Crit Care Med. 2020 Feb;41(1):80-98
pubmed: 32000286
Mycoses. 2018 Nov;61(11):796-813
pubmed: 30098069
Blood. 2001 Mar 15;97(6):1604-10
pubmed: 11238098
Biol Blood Marrow Transplant. 2011 Jul;17(7):1043-50
pubmed: 21087680
Eur J Radiol. 2005 Sep;55(3):437-44
pubmed: 16129254
J Antimicrob Chemother. 2012 Jul;67(7):1746-8
pubmed: 22499998
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
Clin Infect Dis. 2007 Feb 1;44(3):373-9
pubmed: 17205443
Pediatrics. 2008 May;121(5):e1286-94
pubmed: 18450871